Physician profile
Andrea Petty
NPI 1194387886
$3,802.72
in general payments reported to CMS, 2019-2025
14 companies · $593 in 2025
The $593 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $478 · 2022: $617 · 2023: $1,105 · 2024: $1,010 · 2025: $593.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,661 · Education: $46.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,660.71 |
| Education | $46.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,250.05 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $906.87 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $606.93 | 2021-2024 | Spravato |
| Otsuka America Pharmaceutical, INC. | $249.46 | 2021-2023 | Rexulti, Abilify Maintena |
| Corium, LLC | $145.38 | 2022-2023 | Azstarys |
| Alkermes, INC. | $137.39 | 2021-2023 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $137.01 | 2022-2025 | Fanapt |
| Bioxcel Therapeutics, INC. | $112.80 | 2023 | Igalmi |
| Lundbeck LLC | $74.57 | 2023 | Rexulti |
| Idorsia Pharmaceuticals US INC | $51.47 | 2022-2023 | Quviviq |
| Neurocrine Biosciences, INC. | $40.08 | 2021-2022 | |
| Indivior INC. | $39.62 | 2024 | Sublocade |
| Sunovion Pharmaceuticals INC. | $34.82 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Petty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.